Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Alternative polyadenylation of Pax3 controls muscle stem cell fate and muscle function.

de Morree A, Klein JDD, Gan Q, Farup J, Urtasun A, Kanugovi A, Bilen B, van Velthoven CTJ, Quarta M, Rando TA.

Science. 2019 Nov 8;366(6466):734-738. doi: 10.1126/science.aax1694.

PMID:
31699935
2.

Stem Cell Quiescence: Dynamism, Restraint, and Cellular Idling.

van Velthoven CTJ, Rando TA.

Cell Stem Cell. 2019 Feb 7;24(2):213-225. doi: 10.1016/j.stem.2019.01.001. Review.

PMID:
30735649
3.

Intranasal Stem Cell Treatment as a Novel Therapy for Subarachnoid Hemorrhage.

Nijboer CH, Kooijman E, van Velthoven CT, van Tilborg E, Tiebosch IA, Eijkelkamp N, Dijkhuizen RM, Kesecioglu J, Heijnen CJ.

Stem Cells Dev. 2018 Mar 1;27(5):313-325. doi: 10.1089/scd.2017.0148. Epub 2018 Jan 8.

PMID:
29310519
4.

Transcriptional Profiling of Quiescent Muscle Stem Cells In Vivo.

van Velthoven CTJ, de Morree A, Egner IM, Brett JO, Rando TA.

Cell Rep. 2017 Nov 14;21(7):1994-2004. doi: 10.1016/j.celrep.2017.10.037.

5.

Staufen1 inhibits MyoD translation to actively maintain muscle stem cell quiescence.

de Morrée A, van Velthoven CTJ, Gan Q, Salvi JS, Klein JDD, Akimenko I, Quarta M, Biressi S, Rando TA.

Proc Natl Acad Sci U S A. 2017 Oct 24;114(43):E8996-E9005. doi: 10.1073/pnas.1708725114. Epub 2017 Oct 9.

6.

Intronic polyadenylation of PDGFRα in resident stem cells attenuates muscle fibrosis.

Mueller AA, van Velthoven CT, Fukumoto KD, Cheung TH, Rando TA.

Nature. 2016 Dec 8;540(7632):276-279. doi: 10.1038/nature20160. Epub 2016 Nov 28.

7.

Mesenchymal stem cells attenuate MRI-identifiable injury, protect white matter, and improve long-term functional outcomes after neonatal focal stroke in rats.

van Velthoven CT, Dzietko M, Wendland MF, Derugin N, Faustino J, Heijnen CJ, Ferriero DM, Vexler ZS.

J Neurosci Res. 2017 May;95(5):1225-1236. doi: 10.1002/jnr.23954. Epub 2016 Oct 26.

8.

Assessment of long-term safety and efficacy of intranasal mesenchymal stem cell treatment for neonatal brain injury in the mouse.

Donega V, Nijboer CH, van Velthoven CT, Youssef SA, de Bruin A, van Bel F, Kavelaars A, Heijnen CJ.

Pediatr Res. 2015 Nov;78(5):520-6. doi: 10.1038/pr.2015.145. Epub 2015 Aug 13.

9.

The neonatal brain is not protected by osteopontin peptide treatment after hypoxia-ischemia.

Bonestroo HJ, Nijboer CH, van Velthoven CT, van Bel F, Heijnen CJ.

Dev Neurosci. 2015;37(2):142-52. doi: 10.1159/000369093. Epub 2015 Mar 11.

PMID:
25765537
10.

Stem cells for neonatal stroke- the future is here.

van Velthoven CT, Gonzalez F, Vexler ZS, Ferriero DM.

Front Cell Neurosci. 2014 Jul 25;8:207. doi: 10.3389/fncel.2014.00207. eCollection 2014. No abstract available.

11.

Long-term functional consequences and ongoing cerebral inflammation after subarachnoid hemorrhage in the rat.

Kooijman E, Nijboer CH, van Velthoven CT, Mol W, Dijkhuizen RM, Kesecioglu J, Heijnen CJ.

PLoS One. 2014 Mar 6;9(6):e90584. doi: 10.1371/journal.pone.0090584. eCollection 2014.

12.

The rodent endovascular puncture model of subarachnoid hemorrhage: mechanisms of brain damage and therapeutic strategies.

Kooijman E, Nijboer CH, van Velthoven CT, Kavelaars A, Kesecioglu J, Heijnen CJ.

J Neuroinflammation. 2014 Jan 3;11:2. doi: 10.1186/1742-2094-11-2. Review.

13.

Balancing GRK2 and EPAC1 levels prevents and relieves chronic pain.

Wang H, Heijnen CJ, van Velthoven CT, Willemen HL, Ishikawa Y, Zhang X, Sood AK, Vroon A, Eijkelkamp N, Kavelaars A.

J Clin Invest. 2013 Dec;123(12):5023-34. doi: 10.1172/JCI66241. Epub 2013 Nov 15.

14.

Therapeutic potential of genetically modified mesenchymal stem cells after neonatal hypoxic-ischemic brain damage.

van Velthoven CT, Braccioli L, Willemen HL, Kavelaars A, Heijnen CJ.

Mol Ther. 2014 Mar;22(3):645-654. doi: 10.1038/mt.2013.260. Epub 2013 Oct 31.

15.

Cerebral and hepatic inflammatory response after neonatal hypoxia-ischemia in newborn rats.

Bonestroo HJ, Nijboer CH, van Velthoven CT, Kavelaars A, Hack CE, van Bel F, Heijnen CJ.

Dev Neurosci. 2013;35(2-3):197-211. doi: 10.1159/000346685. Epub 2013 May 8.

PMID:
23689428
16.

Mesenchymal stem cell transplantation attenuates brain injury after neonatal stroke.

van Velthoven CT, Sheldon RA, Kavelaars A, Derugin N, Vexler ZS, Willemen HL, Maas M, Heijnen CJ, Ferriero DM.

Stroke. 2013 May;44(5):1426-32. doi: 10.1161/STROKEAHA.111.000326. Epub 2013 Mar 28.

17.

The endogenous regenerative capacity of the damaged newborn brain: boosting neurogenesis with mesenchymal stem cell treatment.

Donega V, van Velthoven CT, Nijboer CH, Kavelaars A, Heijnen CJ.

J Cereb Blood Flow Metab. 2013 May;33(5):625-34. doi: 10.1038/jcbfm.2013.3. Epub 2013 Feb 13. Review.

18.

Intranasal mesenchymal stem cell treatment for neonatal brain damage: long-term cognitive and sensorimotor improvement.

Donega V, van Velthoven CT, Nijboer CH, van Bel F, Kas MJ, Kavelaars A, Heijnen CJ.

PLoS One. 2013;8(1):e51253. doi: 10.1371/journal.pone.0051253. Epub 2013 Jan 3.

19.

Mesenchymal stem cells restore cortical rewiring after neonatal ischemia in mice.

van Velthoven CT, van de Looij Y, Kavelaars A, Zijlstra J, van Bel F, Huppi PS, Sizonenko S, Heijnen CJ.

Ann Neurol. 2012 Jun;71(6):785-96. doi: 10.1002/ana.23543.

PMID:
22718545
20.

Effects of antenatal glucocorticoid therapy on hippocampal histology of preterm infants.

Tijsseling D, Wijnberger LD, Derks JB, van Velthoven CT, de Vries WB, van Bel F, Nikkels PG, Visser GH.

PLoS One. 2012;7(3):e33369. doi: 10.1371/journal.pone.0033369. Epub 2012 Mar 23.

21.

Mesenchymal stem cells as a treatment for neonatal ischemic brain damage.

van Velthoven CT, Kavelaars A, Heijnen CJ.

Pediatr Res. 2012 Apr;71(4 Pt 2):474-81. doi: 10.1038/pr.2011.64. Epub 2012 Feb 8. Review.

PMID:
22430383
22.

Osteopontin enhances endogenous repair after neonatal hypoxic-ischemic brain injury.

van Velthoven CT, Heijnen CJ, van Bel F, Kavelaars A.

Stroke. 2011 Aug;42(8):2294-301. doi: 10.1161/STROKEAHA.110.608315. Epub 2011 Jun 23.

PMID:
21700938
23.

Targeting the p53 pathway to protect the neonatal ischemic brain.

Nijboer CH, Heijnen CJ, van der Kooij MA, Zijlstra J, van Velthoven CT, Culmsee C, van Bel F, Hagberg H, Kavelaars A.

Ann Neurol. 2011 Aug;70(2):255-64. doi: 10.1002/ana.22413. Epub 2011 Jun 14.

PMID:
21674585
24.

Mesenchymal stem cell transplantation changes the gene expression profile of the neonatal ischemic brain.

van Velthoven CT, Kavelaars A, van Bel F, Heijnen CJ.

Brain Behav Immun. 2011 Oct;25(7):1342-8. doi: 10.1016/j.bbi.2011.03.021. Epub 2011 Apr 5.

PMID:
21473911
25.

Modulation of TGF-β/BMP-6 expression and increased levels of circulating smooth muscle progenitor cells in a type I diabetes mouse model.

Westerweel PE, van Velthoven CT, Nguyen TQ, den Ouden K, de Kleijn DP, Goumans MJ, Goldschmeding R, Verhaar MC.

Cardiovasc Diabetol. 2010 Sep 21;9:55. doi: 10.1186/1475-2840-9-55.

26.

Nasal administration of stem cells: a promising novel route to treat neonatal ischemic brain damage.

van Velthoven CT, Kavelaars A, van Bel F, Heijnen CJ.

Pediatr Res. 2010 Nov;68(5):419-22. doi: 10.1203/PDR.0b013e3181f1c289.

PMID:
20639794
28.

GRK2: a novel cell-specific regulator of severity and duration of inflammatory pain.

Eijkelkamp N, Heijnen CJ, Willemen HL, Deumens R, Joosten EA, Kleibeuker W, den Hartog IJ, van Velthoven CT, Nijboer C, Nassar MA, Dorn GW 2nd, Wood JN, Kavelaars A.

J Neurosci. 2010 Feb 10;30(6):2138-49. doi: 10.1523/JNEUROSCI.5752-09.2010.

29.

Mesenchymal stem cell treatment after neonatal hypoxic-ischemic brain injury improves behavioral outcome and induces neuronal and oligodendrocyte regeneration.

van Velthoven CT, Kavelaars A, van Bel F, Heijnen CJ.

Brain Behav Immun. 2010 Mar;24(3):387-93. doi: 10.1016/j.bbi.2009.10.017. Epub 2009 Oct 31.

PMID:
19883750
30.

Regeneration of the ischemic brain by engineered stem cells: fuelling endogenous repair processes.

van Velthoven CT, Kavelaars A, van Bel F, Heijnen CJ.

Brain Res Rev. 2009 Jun;61(1):1-13. doi: 10.1016/j.brainresrev.2009.03.003. Epub 2009 Apr 5. Review.

PMID:
19348860

Supplemental Content

Loading ...
Support Center